Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in ...
LOS ANGELES, CA--(Marketwired - Mar 28, 2017) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) Data Supports Further Clinical Development into Phase 3 Conference call and webcast at 9 a.m. EDT, March 29, 2017 Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the …